ACLARA Appoints Dennis Harris, PhD As Senior Vice President Of Research and Development

Apr 25, 2001, 01:00 ET from ACLARA BioSciences, Inc.

    MOUNTAIN VIEW, Calif., April 25 /PRNewswire Interactive News Release/
 -- ACLARA BioSciences (Nasdaq: ACLA) announced that Dennis Harris, PhD has
 joined the company in the newly created position of Senior Vice President,
 Research and Development.  Dr. Harris joins ACLARA from Amersham Phamacia
 Biotech where he was Vice President of R&D for North America.
     Over the course of a 19-year career at AP Biotech, Dr. Harris successfully
 directed the development of numerous reagent kits and instrument systems for
 life science research, including the MegaBACE(TM) DNA sequencer and associated
 reagents.  In his most recent position, Dr. Harris had responsibility for
 AP Biotech's global genomics R&D strategy, and managed a North American R&D
 organization of approximately 250 scientists and engineers.
     "We are very pleased to expand our senior management team with someone of
 Dennis' stature," stated Joseph M. Limber, President and CEO.  "He brings to
 ACLARA an outstanding record of developing and commercializing advanced tools
 for life science research."
     Dr. Harris commented, "ACLARA is a unique company, with its combination of
 leading edge microfluidic technologies and novel chemistries.  I was attracted
 to this position both by the breadth of technologies and by the quality and
 energy of the people.  I really believe we have a tremendous opportunity to
 deliver truly enabling and sustainable products to the Life Scientist.  I am
 excited to be a part of the team and committed to helping ACLARA become a
 significant force in the Life Sciences."
     ACLARA BioSciences is a leading developer of lab-on-a-chip and enabling
 assay technologies for life science research.  The company is developing
 advanced tools for drug discovery, genomics and proteomics using its
 proprietary microfluidics array technology and eTag(TM) assay chemistries.  By
 performing integrated sample processing and analysis on plastic microfluidic
 array LabCard chips, these tools enable the rapid, parallel processing of
 large numbers of samples while requiring only minute volumes of expensive or
 rare reagents.
     The foregoing discussion involves risks and uncertainty.  These and other
 risks related to ACLARA are under the heading "Risk Factors" contained in
 ACLARA's SEC filings, including on Form 10-K filed April 2, 2001.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X71681105
 
 

SOURCE ACLARA BioSciences, Inc.
    MOUNTAIN VIEW, Calif., April 25 /PRNewswire Interactive News Release/
 -- ACLARA BioSciences (Nasdaq: ACLA) announced that Dennis Harris, PhD has
 joined the company in the newly created position of Senior Vice President,
 Research and Development.  Dr. Harris joins ACLARA from Amersham Phamacia
 Biotech where he was Vice President of R&D for North America.
     Over the course of a 19-year career at AP Biotech, Dr. Harris successfully
 directed the development of numerous reagent kits and instrument systems for
 life science research, including the MegaBACE(TM) DNA sequencer and associated
 reagents.  In his most recent position, Dr. Harris had responsibility for
 AP Biotech's global genomics R&D strategy, and managed a North American R&D
 organization of approximately 250 scientists and engineers.
     "We are very pleased to expand our senior management team with someone of
 Dennis' stature," stated Joseph M. Limber, President and CEO.  "He brings to
 ACLARA an outstanding record of developing and commercializing advanced tools
 for life science research."
     Dr. Harris commented, "ACLARA is a unique company, with its combination of
 leading edge microfluidic technologies and novel chemistries.  I was attracted
 to this position both by the breadth of technologies and by the quality and
 energy of the people.  I really believe we have a tremendous opportunity to
 deliver truly enabling and sustainable products to the Life Scientist.  I am
 excited to be a part of the team and committed to helping ACLARA become a
 significant force in the Life Sciences."
     ACLARA BioSciences is a leading developer of lab-on-a-chip and enabling
 assay technologies for life science research.  The company is developing
 advanced tools for drug discovery, genomics and proteomics using its
 proprietary microfluidics array technology and eTag(TM) assay chemistries.  By
 performing integrated sample processing and analysis on plastic microfluidic
 array LabCard chips, these tools enable the rapid, parallel processing of
 large numbers of samples while requiring only minute volumes of expensive or
 rare reagents.
     The foregoing discussion involves risks and uncertainty.  These and other
 risks related to ACLARA are under the heading "Risk Factors" contained in
 ACLARA's SEC filings, including on Form 10-K filed April 2, 2001.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X71681105
 
 SOURCE  ACLARA BioSciences, Inc.